Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1135 of 6351
-
Liver cancer drug combo shows promise in large trial
Disease control CompletedThis randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the bo…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ovarian cancer drug combo shows promise in slowing disease
Disease control OngoingTo compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemia
Disease control OngoingThis study is an investigational approach that uses immune cells, called "T cells", to kill leukemia. These T cells are removed from blood, modified in a laboratory, and then put back in the body. T cells fight infections and can also kill cancer cells in some cases. However, rig…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for kids with hard-to-treat leukemia: experimental combo shows promise
Disease control CompletedThe purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone and to assess the feasibility and safety of …
Phase 1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a longer hospital stay save lives? a nationwide study investigates
Knowledge-focused OngoingThe current study aims to evaluate the impact of long (\>5 days) and/or compulsory psychiatric inpatient care on subsequent healthcare utilization for self-harm and suicide in people with borderline personality disorder, a condition characterized by frequent self-harm. The basis…
Sponsor: Lund University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New hope for rare leukemia: aggressive combo therapy shows promise
Disease control CompletedPlasma cell leukaemia is a rare variety of multiple myeloma with a poor prognosis. Plasma cell leukaemia is defined as: at least 2,000 circulating plasma cells per µL for a blood leukocyte count higher than 10,000/µL or 20% of plasma cells for a leukocyte count less than 10,000/µ…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC
-
Can a Pre-Surgery skin coating stop wound infections?
Prevention Stopped earlyThe purpose of this study is to prove a reduction of postoperative wound infections after direct preoperative use of a microbial sealant in the form of Integuseal for vascular procedures on lower extremities.
Sponsor: Rijnstate Hospital • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Which antibiotic wins the battle against chlamydia in teens?
Disease control CompletedChlamydia is a common infection among youth and can be given from one person to another during sex. Many people who have chlamydia have no signs of infection at all, but can pass the infection to anyone they have sex with. If not treated, chlamydia can lead to serious health prob…
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Diabetes drug could help eradicate hidden leukemia cells
Disease control CompletedThis project is a Phase II clinical trial that aims at evaluating efficacy and tolerance of the combination of pioglitazone (Actos®) and imatinib mesylate (STI571, CGP57148, Gleevec®) in patients with Chronic Myelogenous Leukemia (CML) in stable major molecular response (i.e. a B…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Free meds could boost quit rates in stroke survivors
Disease control CompletedResearch Aims The aims of this research study are to determine whether cost-free smoking cessation pharmacotherapy: 1. Helps smokers with Transient Ischemic Attack (TIA) or stroke to quit smoking over the long-term, compared to simply providing a prescription for these medicati…
Phase 4 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could adding chemo to radiation tame Slow-Growing brain tumors?
Disease control OngoingRATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide,…
Phase 3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to treatment, or primary peritoneal cancer. Veliparib …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo aims to shrink metastatic kidney tumors
Disease control OngoingThis phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body. Entinostat may stop the growth of tumor cells by blo…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Own immune cells shrink tumors in advanced melanoma trial
Disease control CompletedThe overall purpose of this research study is to find a better way to treat melanoma. This will be a single arm exploratory trial to evaluate prospectively the feasibility of, the toxicities of, and the persistence of TIL which can survive in vivo.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Less invasive surgery may cut complications in esophageal cancer patients
Disease control CompletedTo compare laparoscopically-assisted gastric mobilization versus open gastric mobilization in Ivor-Lewis esophagectomy for esophageal cancer, with open thoracic approach in the 2 arms.
Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a transplant drug tame tough vascular birthmarks?
Disease control CompletedThe purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved clinical status and quality of life. Funding Source - FD…
Phase 2 • Sponsor: Denise Martin Adams • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Last hope? new combo targets myeloma that resists standard drugs
Disease control CompletedThe purpose of this study is to evaluate the response to pomalidomide and dexamethasone in relapse and refractory MM patients who are progressive and did not achieve at least a partial response to bortezomib and lenalidomide. This study will determine the efficacy and toxicity pr…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a malaria drug help lung cancer patients stay ahead of resistance?
Disease control OngoingThe purpose of this research study is to learn if adding hydroxychloroquine (HCQ) to erlotinib helps treat non-small cell lung cancer (NSCLC). Another goal of this research study is to learn more about NSCLC and how it may respond to study treatment. Erlotinib (Tarceva) is a type…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for kids with liver cancer: personalized treatment shows promise
Disease control CompletedThis phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary, liver transplant, are the main current treatments for h…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drug…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC